In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on TherapeuticsMD (TXMD), with a price target of $7.00. The company’s shares closed last Monday at $2.69.
According to TipRanks.com, Tsao is a 1-star analyst with an average return of -1.8% and a 46.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Minerva Neurosciences, Amag Pharmaceuticals, and Revance Therapeutics.
TherapeuticsMD has an analyst consensus of Strong Buy, with a price target consensus of $11.80.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.09 and a one-year low of $1.82. Currently, TherapeuticsMD has an average volume of 3.33M.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TXMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
